Abstract

BackgroundIn Rheumatoid Arthritis (RA) and Osteoarthritis (OA) forefoot involvement causes disability and metatharsalgia.Objectivesto evaluate, in RA and OA patients, the efficacy of two programs combining insoles in polypropylene terephtalate (PPT)...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Comparison of Foot Kinematics and Foot Plantar Area and Pressure Among Five Different Closed Kinematic Tasks.
Renan A Resende ... Diego José A Telarolli
Journal of the American Podiatric Medical Association | VOL. 110
Renan A Resende, et. al.Renan A Resende ... Diego José A Telarolli
01 Sep 2020
FRI0549 Osteoarthritis (OA) and rheumatoid arthritis (RA) patients have similar disease burdens at first visit to an academic rheumatology setting, but oa patients have a higher burden at a 6-month follow-up visit
A.-M Malfait ... J.A Block
Annals of the Rheumatic Diseases | VOL. 77
A.-M Malfait, et. al.A.-M Malfait ... J.A Block
01 Jun 2018
THU0448 DISEASE BURDEN IN OSTEOARTHRITIS (OA) IS SIMILAR TO RHEUMATOID ARTHRITIS (RA) FROM THE PATIENT’S PERSPECTIVE, SLIGHTLY HIGHER IN RA AT PRESENTATION, SIMILAR ONE YEAR LATER, AND SLIGHTLY HIGHER IN OA TWO YEARS LATER AT ONE PRIVATE PRACTICE SETTING
Theodore Pincus ... Martin Bergman
-
Theodore Pincus, et. al.Theodore Pincus ... Martin Bergman
01 Jun 2019
SAT0451 Quality of sleep (QOS) and quality of life (QOL) in patients with osteoarthritis and rheumatoid arthritis
...
Annals of the Rheumatic Diseases | VOL. 71
, et. al. ...
01 Jun 2013
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations
Myrto Kostopoulou ... Antonis Fanouriakis
Annals of the Rheumatic Diseases | VOL. -
Myrto Kostopoulou, et. al.Myrto Kostopoulou ... Antonis Fanouriakis
22 May 2024
View more papers